• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Global Blood Therapeutics (GBT) announces upcoming data presentations supporting Voxelotor SCD program


Global Blood Therapeutics, Inc. (GBT) today announced that four abstracts related to the voxelotor program in sickle cell disease will be presented during the Foundation for Sickle Cell Disease Research’s (FSCDR) 12th Annual SCD Research and Educational Symposium in Washington, D.C., taking place June 15-17, 2018. 

Four encore abstracts have been accepted, including three for oral presentation. Additionally, Kenneth R. Bridges, M.D., vice president, medical affairs at GBT, will be discussing voxelotor as part of the Investigational New Drugs, Therapeutic and Device Symposium on Friday, June 15, from 4:30-6:30 p.m. Eastern Time (ET). The abstracts are now available for symposium attendees through the FSCDR 2018 app.